Related Experiment Videos
Manipulating mitochondrial DNA heteroplasmy by a mitochondrially targeted restriction endonuclease
1Department of Cell Biology and Anatomy, Department of Neurology, University of Miami School of Medicine, 1095 NW 14th Terrace, Miami, FL 33136, USA.
Abstract:
Mutations in the mitochondrial DNA (mtDNA) can cause a variety of human diseases. In most cases, such mutations are heteroplasmic (i.e. mutated and wild-type mtDNA coexist) and a small percentage of wild-type sequences can have a strong protective effect against a metabolic defect. Because a genetic approach to correct mtDNA mutations is not currently available, the ability to modulate heteroplasmy would have a major impact in the phenotype of many patients with mitochondrial disorders. We show here that a restriction endonuclease targeted to mitochondria has this ability. A mitochondrially targeted PstI degraded mtDNA harboring PstI sites, in some cases leading to a complete loss of mitochondrial genomes. Recombination between DNA ends released by PstI was not observed. When expressed in a heteroplasmic rodent cell line, containing one mtDNA haplotype with two sites for PstI and another haplotype having none, the mitochondrial PstI caused a significant shift in heteroplasmy, with an accumulation of the mtDNA haplotype lacking PstI sites. These experiments provide proof of the principle that restriction endonucleases are feasible tools for genetic therapy of a sub-group of mitochondrial disorders. Although this approach is limited by the presence of mutation-specific restriction sites, patients with neuropathy, ataxia and retinitis pigmentosa (NARP) could benefit from it, as the T8399G mutation creates a unique restriction site that is not present in wild-type human mitochondrial DNA.
Insights
Targeting mitochondria with restriction enzymes can shift harmful mitochondrial DNA (mtDNA) heteroplasmy. This approach shows promise for treating mitochondrial disorders by reducing mutated mtDNA sequences.
Area of Science:
- Mitochondrial genetics
- Molecular biology
- Genetic therapy
Background:
- Mitochondrial DNA (mtDNA) mutations cause human diseases, often presenting as heteroplasmy (coexistence of mutated and wild-type mtDNA).
- Wild-type mtDNA can offer protection against metabolic defects in heteroplasmic conditions.
- Current genetic therapies for mtDNA mutations are limited, highlighting the need for methods to modulate heteroplasmy.
Purpose of the Study:
- To investigate the potential of mitochondrially targeted restriction endonucleases to modulate mtDNA heteroplasmy.
- To demonstrate proof-of-principle for using restriction enzymes as a therapeutic tool for mitochondrial disorders.
Main Methods:
- Mitochondrially targeted PstI endonuclease was engineered to degrade mtDNA containing specific PstI restriction sites.
- Experiments were conducted in a heteroplasmic rodent cell line with distinct mtDNA haplotypes (one with PstI sites, one without).
- The effect of the endonuclease on heteroplasmy levels and potential for DNA recombination was assessed.
Main Results:
- Mitochondrially targeted PstI successfully degraded mtDNA harboring PstI sites, leading to a significant shift in heteroplasmy.
- The endonuclease treatment resulted in an accumulation of the mtDNA haplotype lacking PstI sites.
- No evidence of recombination between DNA ends released by PstI was observed.
Conclusions:
- Restriction endonucleases targeted to mitochondria are feasible tools for modulating mtDNA heteroplasmy.
- This approach offers a potential therapeutic strategy for specific mitochondrial disorders, such as NARP, where mutations create unique restriction sites.
- The efficacy is dependent on the presence of mutation-specific restriction sites within the mtDNA.